Results 61 to 70 of about 10,960 (146)
The emergence of Klebsiella pneumoniae carbapenemases (KPCs), β-lactamases that inactivate “last-line” antibiotics such as imipenem, represents a major challenge to contemporary antibiotic therapies.
Melissa D. Barnes +11 more
doaj +1 more source
Background Bloodstream infection (BSI) is associated with poor outcomes especially when effective antimicrobial therapy and control of infection source are delayed.
Helio S. Sader +3 more
doaj +1 more source
Antimicrobial resistance is a major global health issue. Metallo-β-lactamases (MBL), in particular, are problematic because they can inactivate all classes of β-lactams except aztreonam.
Małgorzata Brauncajs +3 more
doaj +1 more source
Allergic Reactions and Cross-Reactivity Potential with Beta-Lactamase Inhibitors
Although beta-lactam allergies are an emerging focus of stewardship programs and interventions, less is publicly released regarding allergies to beta-lactamase inhibitors. This review presents and evaluates the data regarding allergic reactions with beta-
Kayla R. Stover +2 more
doaj +1 more source
Cefiderocol, a siderophore-cephalosporine conjugate antibiotic, shows promise as a therapeutic option for carbapenem-resistant (CR) Acinetobacter infections. While resistance has already been reported in A. baumannii, combination therapies with avibactam
Olivia Wong +9 more
doaj +1 more source
BACKGROUND: Guideline-based therapy (GBT) of Mycobacterium abscessus (MAB) lung disease (LD) achieves a sputum culture conversion rate in ∼35% of patients. The β-lactam antibiotics, imipenem and cefoxitin, are the cornerstone of GBT.
B.E. Ferro, S. Srivastava, T. Gumbo
doaj +1 more source
The escalating crisis of multidrug resistance, together with the persistence of antibiotic residues in clinical and environmental matrices, demands integrated strategies that couple sensitive detection, efficient decontamination, and controlled delivery.
Jackson J. Alcázar +2 more
doaj +1 more source
Carbapenems, often regarded as the last line of defense in treatment of urinary tract infections and urosepsis caused by Escherichia coli, are under pressure from emerging resistance.
Mikaela M. Walker +8 more
doaj +1 more source
Erratum: Cefdinir and β-Lactamase Inhibitor Independent Efficacy Against Mycobacterium tuberculosis
Frontiers Production Office
doaj +1 more source
The novel antibiotic ceftazidime-avibactam was introduced in Korea in 2023. This study evaluated the in vitro susceptibility of Pseudomonas aeruginosa isolates from a community-based hospital to various antibiotics, including ceftazidime-avibactam.
Lee Hyo-Jin +6 more
doaj +1 more source

